- The Body

The Body Covers: The 52nd Annual Meeting of the American Association for the Study of Liver Diseases

Coverage provided by Luis Balart M.D., F.A.C.G.

November 12, 2001

This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Effect of HAART on Liver-Related Mortality in HIV/HCV Co-Infected Patients (Poster 1027)
Authored by Nazifa Qurishi, et al., University of Bonn, Bonn, Germany

Investigators at the Universitaetsklinikum in Bonn, Germany report their experience with co-infected patients. It has been widely reported that hepatitis C infection takes a more aggressive course in HIV/HCV co-infected patients and can lead to advanced liver disease such as cirrhosis, liver failure and hepatocellular carcinoma. With the introduction of HAART and longer survival, it's been theorized that co-infected patients may have increased morbidity and mortality from hepatitis C infection.

The objective of this study was to clarify whether HAART in fact affects liver-related and total mortality in co-infected patients. This was a retrospective study of the Bonn HIV Cohort which has been followed since 1990. The study group consisted of 285 patients, of whom 94 had received HAART. In the entire group, 107 patients died and 25 of these deaths were liver-related.

In the patients receiving HAART, only eight deaths were observed and only two of these deaths were related to HCV-related liver disease. Kaplan-Meyer survival analysis confirmed a total survival benefit for the HIV/HCV co-infected patients receiving HAART with a mean survival of 2,658 days versus 1,679 days. HAART-treated patients also had lower liver-related mortality, surviving a mean of 2,186 days versus 2,119 days; however, this difference did not reach statistical significance.

This study shows that HAART reduces mortality in HIV/HCV co-infected patients just as it does in non-co-infected patients. Most importantly, this study does not support the hypothesis that liver-related mortality increases in HIV/HCV co-infected patients receiving HAART therapy and therefore there is no rationale to withhold HAART from HIV/HCV co-infected patients.

Previous | Next

This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

More on Hepatitis C

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.